<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Oncolytics Biotech Inc — News on 6ix</title>
<link>https://6ix.com/company/oncolytics-biotech-inc</link>
<description>Latest news and press releases for Oncolytics Biotech Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 06 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/oncolytics-biotech-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835fb9d78dffbe2df131d6f.webp</url>
<title>Oncolytics Biotech Inc</title>
<link>https://6ix.com/company/oncolytics-biotech-inc</link>
</image>
<item>
<title>Oncolytics Biotech&#xAE; Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-announces-type-c-fda-meeting-to-discuss-single-arm-registrational-pathway-for-pelareorep-in-anal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-announces-type-c-fda-meeting-to-discuss-single-arm-registrational-pathway-for-pelareorep-in-anal-cancer</guid>
<pubDate>Mon, 06 Apr 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech &#xAE; Inc. (Nasdaq: ONCY) (&#x...</description>
</item>
<item>
<title>Oncolytics Biotech&#xAE; Completes Domicile Change to the United States</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-completes-domicile-change-to-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-completes-domicile-change-to-the-united-states</guid>
<pubDate>Wed, 01 Apr 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech &#xAE; Inc. (Nasdaq: ONCY) (&#x...</description>
</item>
<item>
<title>Oncolytics Biotech&#xAE; to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-to-present-new-mechanistic-and-translational-data-supporting-pelareorep-as-an-immune-priming-backbone-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-to-present-new-mechanistic-and-translational-data-supporting-pelareorep-as-an-immune-priming-backbone-at-aacr-2026</guid>
<pubDate>Thu, 19 Mar 2026 13:00:00 GMT</pubDate>
<description>Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formati...</description>
</item>
<item>
<title>Oncolytics Biotech&#xAE; Launches Randomized Colorectal Cancer Study</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-launches-randomized-colorectal-cancer-study</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-launches-randomized-colorectal-cancer-study</guid>
<pubDate>Mon, 02 Mar 2026 14:00:00 GMT</pubDate>
<description>Controlled study designed to confirm previous compelling efficacy with preliminary data expected ...</description>
</item>
<item>
<title>Oncolytics Biotech&#xAE; to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-to-prioritize-registration-focused-programs-in-anal-and-colorectal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-to-prioritize-registration-focused-programs-in-anal-and-colorectal-cancer</guid>
<pubDate>Tue, 24 Feb 2026 14:00:00 GMT</pubDate>
<description>Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. ...</description>
</item>
<item>
<title>Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-receives-fda-fast-135000618</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-receives-fda-fast-135000618</guid>
<pubDate>Wed, 04 Feb 2026 13:50:00 GMT</pubDate>
<description>Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant MSS mCRC with interim data expected by the end of 2026 Pelareorep now has Fast Track Designation for two gastrointestinal cancers, solidifying its potential as an immunotherapeutic platform therapy in gastrointestinal cancers SAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nas</description>
</item>
<item>
<title>Oncolytics Biotech&#xAE; Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-receives-fda-fast-track-designation-for-pelareorep-in-2l-kras-mutant-mss-metastatic-colorectal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-receives-fda-fast-track-designation-for-pelareorep-in-2l-kras-mutant-mss-metastatic-colorectal-cancer</guid>
<pubDate>Wed, 04 Feb 2026 13:50:00 GMT</pubDate>
<description>Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by...</description>
</item>
<item>
<title>Oncolytics Biotech&#xAE; Announces Results of Special Meeting of Shareholders</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-announces-results-of-special-meeting-of-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-announces-results-of-special-meeting-of-shareholders</guid>
<pubDate>Thu, 15 Jan 2026 21:01:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech &#xAE; Inc. (Nasdaq: ONCY) (&#x2...</description>
</item>
<item>
<title>Oncolytics Biotech&#xAE; Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-appoints-john-mcadory-as-evp-of-strategy-and-operations-and-yujun-wu-to-lead-biostatistics</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-appoints-john-mcadory-as-evp-of-strategy-and-operations-and-yujun-wu-to-lead-biostatistics</guid>
<pubDate>Wed, 14 Jan 2026 14:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech &#xAE; Inc. (Nasdaq: ONCY) (&#x2...</description>
</item>
<item>
<title>Oncolytics Biotech&#xAE; Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-announces-updated-clinical-data-from-goblet-cohort-4-demonstrating-activity-of-pelareorep-plus-atezolizumab-in-third-line-anal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-announces-updated-clinical-data-from-goblet-cohort-4-demonstrating-activity-of-pelareorep-plus-atezolizumab-in-third-line-anal-cancer</guid>
<pubDate>Mon, 12 Jan 2026 14:00:00 GMT</pubDate>
<description>Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR&#xA0; Combin...</description>
</item>
<item>
<title>Oncolytics Biotech&#xAE; Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-outlines-strategic-rationale-for-proposal-to-change-jurisdiction-of-incorporation-to-nevada</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-outlines-strategic-rationale-for-proposal-to-change-jurisdiction-of-incorporation-to-nevada</guid>
<pubDate>Fri, 09 Jan 2026 14:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech &#xAE; Inc. (Nasdaq: ONCY) (&#x2...</description>
</item>
<item>
<title>Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/positive-phase-3-results-support-ziiherar-as-her2-targeted-therapy-of-choice-and-combination-with-tevimbrar-and-chemotherapy-as-new-standard-of-care-in-first-line-her2-positive-locally-advanced-or-metastatic-gastroesophageal-adenocarcinoma</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/positive-phase-3-results-support-ziiherar-as-her2-targeted-therapy-of-choice-and-combination-with-tevimbrar-and-chemotherapy-as-new-standard-of-care-in-first-line-her2-positive-locally-advanced-or-metastatic-gastroesophageal-adenocarcinoma</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>ZIIHERA plus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and</description>
</item>
<item>
<title>Oncolytics Biotech® Announces Upcoming Investor Conferences in September</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-announces-upcoming-investor-123000980</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-announces-upcoming-investor-123000980</guid>
<pubDate>Thu, 28 Aug 2025 12:30:00 GMT</pubDate>
<description>Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, will participate in two investor conferences next month. CEO Jared Kelly will be meeting with institutional investors at the H.C. Wainwright 27th Annual Global Investment Conference and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference. Additional details for both of these events can be found below.</description>
</item>
<item>
<title>Biotech Stocks Rally as Oncology Market Targets $866B by 2034</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/biotech-stocks-rally-as-oncology-market-targets-dollar866b-by-2034</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/biotech-stocks-rally-as-oncology-market-targets-dollar866b-by-2034</guid>
<pubDate>Thu, 14 Aug 2025 16:30:00 GMT</pubDate>
<description>Biotech Stocks Rally as Oncology Market Targets $866B by 2034 Canada NewsWire ...</description>
</item>
<item>
<title>Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/cancer-treatment-stocks-surge-as-dollar866b-market-attracts-private-investment</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/cancer-treatment-stocks-surge-as-dollar866b-market-attracts-private-investment</guid>
<pubDate>Thu, 14 Aug 2025 16:22:00 GMT</pubDate>
<description>Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment Canada NewsWi...</description>
</item>
<item>
<title>Oncolytics Biotech&#xAE; Announces Voting Results from the Annual General Meeting of Shareholders</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-announces-voting-results-from-the-annual-general-meeting-of-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotechandxae-announces-voting-results-from-the-annual-general-meeting-of-shareholders</guid>
<pubDate>Mon, 11 Aug 2025 20:55:00 GMT</pubDate>
<description>Oncolytics Biotech&#xAE; Announces Voting Results from the Annual General Meeting of Shareholders...</description>
</item>
<item>
<title>Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-announces-voting-results-205500130</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-announces-voting-results-205500130</guid>
<pubDate>Mon, 11 Aug 2025 20:55:00 GMT</pubDate>
<description>Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.</description>
</item>
<item>
<title>Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-reports-second-quarter-130500073</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-reports-second-quarter-130500073</guid>
<pubDate>Fri, 08 Aug 2025 13:05:00 GMT</pubDate>
<description>Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today reported financial results and recent highlights for the second quarter of 2025. All dollar amounts are expressed in Canadian currency unless otherwise noted.</description>
</item>
<item>
<title>Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-announces-voluntary-delisting-130000093</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-announces-voluntary-delisting-130000093</guid>
<pubDate>Fri, 08 Aug 2025 13:00:00 GMT</pubDate>
<description>Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that the common shares in the capital of the Company (the "Shares") will be voluntarily delisted from the Toronto Stock Exchange ("TSX") at the close of markets on August 22, 2025, pursuant to the Company's application for voluntary delisting and the satisfaction of the conditions to delist from the TSX. The delisting from the TSX will</description>
</item>
<item>
<title>Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results</title>
<link>https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-announces-upcoming-annual-123000737</link>
<guid isPermaLink="true">https://6ix.com/company/oncolytics-biotech-inc/news/oncolytics-biotech-announces-upcoming-annual-123000737</guid>
<pubDate>Tue, 05 Aug 2025 12:30:00 GMT</pubDate>
<description>Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that its upcoming 2025 Annual General Meeting (the "Meeting") will be held virtually at 10:00 a.m. Eastern Time (ET) on Friday, August 8, 2025, as a virtual-only shareholder meeting. After the Meeting and at the conclusion of shareholder voting, Oncolytics' Chief Executive Officer, Jared Kelly, will provide a corporate update, including</description>
</item>
</channel>
</rss>